Reviewing Lipocine (NASDAQ:LPCN) & Integrated BioPharma (OTCMKTS:INBP)

Integrated BioPharma (OTCMKTS:INBP) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Earnings and Valuation

This table compares Integrated BioPharma and Lipocine”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated BioPharma	$54.35 million	0.10	$810,000.00	($0.07)	-2.57
Lipocine	$1.98 million	9.95	-$9.63 million	($1.88)	-1.27

Integrated BioPharma has higher revenue and earnings than Lipocine. Integrated BioPharma is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Integrated BioPharma has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.

Institutional & Insider Ownership

25.3% of Integrated BioPharma shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 67.4% of Integrated BioPharma shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Integrated BioPharma and Lipocine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated BioPharma	-3.43%	-8.32%	-6.57%
Lipocine	-571.18%	-66.70%	-59.39%

Analyst Ratings

This is a breakdown of current recommendations for Integrated BioPharma and Lipocine, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated BioPharma	0	0	0	0	0.00
Lipocine	1	1	0	1	2.33

Lipocine has a consensus target price of $15.00, indicating a potential upside of 527.62%. Given Lipocine’s stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Integrated BioPharma.

Summary

Integrated BioPharma beats Lipocine on 8 of the 14 factors compared between the two stocks.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.